Abnormal Uterine Bleeding (AUB) is a prevalent disorder often managed with progestin therapy. Systemic delivery of Levonorgestrel (LNG) can lead to elevated plasma levels, increasing the risk of breast cancer. Intravaginal Rings (IVRs) provide a localized delivery route, minimizing systemic exposure and improving patient compliance. Intravaginal rings (IVRs) fabricated from silicone, ethylene-vinyl acetate (EVA), and polyurethane (PU) were evaluated for controlled release of levonorgestrel (LNG) as a localized therapy for abnormal uterine bleeding (AUB).